Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine

References

• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Rudiger T, Weisenburger D D, Anderson J R, Armitage J O, Diebold J, MacLennan K A, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140–149
   PubMed Web of Science ®Google Scholar
• Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini J M, et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999; 32: 545–552
   PubMed Web of Science ®Google Scholar
• Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V, et al. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 2002; 43: 805–811
   PubMed Web of Science ®Google Scholar
• Savage K J, Chhanabhai M, Gascoyne R D, Connors J M. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467–1475
   PubMed Web of Science ®Google Scholar
• Ferry J A. Angioimmunoblastic T-cell lymphoma. Adv Anat Pathol 2002; 9: 273–279
   PubMed Web of Science ®Google Scholar
• Ohshima K, Haraoka S, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M. Cytoplasmic cytokines in lymphoproliferative disorders: multiple cytokine production in angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma 2000; 38: 541–545
   PubMed Web of Science ®Google Scholar
• Pizzolo G, Vinante F, Agostini C, Zambello R, Trentin L, Masciarelli M, et al. Immunologic abnormalities in angioimmunoblastic lymphadenopathy. Cancer 1987; 60: 2412–2418
   PubMed Web of Science ®Google Scholar
• Siegert W, Agthe A, Griesser H, Schwerdtfeger R, Brittinger G, Engelhard M, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992; 117: 364–370
   PubMed Web of Science ®Google Scholar
• Dogan A, Attygalle A D, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol 2003; 121: 681–691
   PubMed Web of Science ®Google Scholar
• Schetelig J, Fetscher S, Reichle A, Berdel W E, Beguin Y, Brunet S, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003; 88: 1272–1278
   PubMed Web of Science ®Google Scholar
• Murayama T, Imoto S, Takahashi T, Ito M, Matozaki S, Nakagawa T. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with Cyclosporin A. Cancer 1992; 69: 2567–2570
   PubMed Web of Science ®Google Scholar
• Takemori N, Kodaira J, Toyoshima N, Sato T, Sakurai H, Akakura N, et al. Successful treatment of immunoblastic lymphadenopathy-like T-cell lymphoma with Cyclosporin A. Leuk Lymphoma 1999; 35: 389–395
   PubMed Web of Science ®Google Scholar
• Advani R, Warnke R, Sikic B I, Horning S. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol 1997; 8: 601–603
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshoff K, Smithers D W, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Han C W, Imamura M, Hashino S, Zhu X, Tanaka J, Imai K, et al. Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression. Bone Marrow Transplant 1995; 15: 733–739
   PubMed Web of Science ®Google Scholar
• Crabtree G R. Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell 1999; 96: 611–614
   PubMed Web of Science ®Google Scholar
• Jones D, O'Hara C, Kraus M D, Perez-Atayde A R, Shahsafaei A, Wu L, et al. Expression pattern of T-cell associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 2000; 96: 685–690
   PubMed Web of Science ®Google Scholar
• Grogg K L, Attygalle A D, Macon W R, Remstein E D, Kurtin P J, Dogan A. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?. Blood 2005; 106: 1501–1502
   PubMed Web of Science ®Google Scholar
• Yamamura M, Honda M, Yamada Y, Itoyama T, Sohda H, Yubashi T, et al. Increased levels of interleukin-6 (IL-6) in serum and spontaneous in vitro production of IL-6 by lymph node mononuclear cells of patients with angio-immunoblastic lymphadenopathy with dysproteinemia (AILD), and clinical effectiveness of cyclosporin A. Leukemia 1996; 10: 1504–1508
   PubMed Web of Science ®Google Scholar
• Weiss L M, Jaffe E S, Liu X F, Chen Y Y, Shibata D, Medeiros L J. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992; 79: 1789–1795
   PubMed Web of Science ®Google Scholar
• Luzzatto F, Pruneri G, Benini E, Manzotti M, Laszlo D, Martinelli G, et al. Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres and a high content of EBV-infected large B-cells carrying IgH chain gene monoclonal rearrangement. Histopathology 2005; 46: 464–466
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Fend F, Moguel L R, Spilove L, Beaty M W, Kingma D W, et al. Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am J Surg Pathol 1999; 23: 1233–1240
   PubMed Web of Science ®Google Scholar
• Brauninger A, Spieker T, Willenbrock K, Gaulard P, Wacker H H, Rajewsky K, et al. Survival and clonal expansion of mutating “forbidden” (immunoglobulin receptor-deficient) epstein-barr virus-infected b cells in angioimmunoblastic t cell lymphoma. J Exp Med 2001; 194: 927–940
   PubMed Web of Science ®Google Scholar
• Battegay M, Berger C, Rochlitz C, Hurwitz N, Hirsch H H, De Geyter C, et al. Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma. Antivir Ther 2004; 9: 453–459
   PubMed Web of Science ®Google Scholar